Insight Molecular Diagnostics Inc. Capital Expenditures Incurred but Not yet Paid
Insight Molecular Diagnostics Inc. (IMDX) reported Capital Expenditures Incurred but Not yet Paid of $139.00 thousand for the 3-month period ending 2021-03-31, per its 10-Q filed 2021-05-17.
Discontinued › Cash Flow › Other Cash Flow Items
us-gaap:CapitalExpendituresIncurredButNotYetPaid · last filed 2021-05-17
- Insight Molecular Diagnostics Inc. capital expenditures incurred but not yet paid for the quarter ending 2021-03-31 was $139.00K.
- Insight Molecular Diagnostics Inc. capital expenditures incurred but not yet paid for fiscal 2020 was $2.05M.
| Period end | Capital Expenditures Incurred but Not yet Paid 3 month | Capital Expenditures Incurred but Not yet Paid 12 month |
|---|---|---|
| 2021-03-31 | $139.00K 10-Q · filed 2021-05-17 | |
| 2020-12-31 | $2.05M 10-K · filed 2021-03-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |
| Cardio Diagnostics Holdings, Inc. (CDIO) | United States | $0.006B | |
| VOLITIONRX LTD (VNRX) | $0.003B | -0.64 | |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |